Determination of the reference value of the incremental cost-efficacy and cost-utility coefficient in Russia in oncology
The share of antineoplastic drug dossiers submitted to reimbursement in Russia raised from 15% in 2014 to 28% in 2017. The effectiveness and safety of innovative anti-cancer therapy is higher comparing to widely used traditional treatments. At the mean time the costs of innovative anti-cancer care a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Izdatelstvo OKI,
2018-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |